Tags

Type your tag names separated by a space and hit enter

Pharmacological Properties of Faster-Acting Insulin Aspart.
Curr Diab Rep 2017; 17(11):101CD

Abstract

PURPOSE OF REVIEW

Faster aspart is a new formulation of insulin aspart (IAsp) produced by adding the excipients niacinamide and L-arginine. As this new, "ultra-rapid insulin" is available in the EU-market and Canada, the pharmacokinetic and pharmacodynamics data is summarized.

RECENT FINDINGS

Faster aspart shows an earlier onset of appearance of insulin in the bloodstream after subcutaneous administration and an earlier onset of glucose-lowering action and a higher glycemic effect within the first 30 min. Faster aspart administered by pump is indeed faster than conventional aspart with a faster on (- 11 min), faster off (- 24 min), and more than 100% greater insulin action within the first 30 min. Tolerability of faster aspart is similar to that of Iasp; the same holds true for compatibility in pump use. Faster aspart shows a faster occurrence of insulin in the blood compared with IAsp in subcutaneous injection. Improvements over current analogs may be more pronounced in pumps than with injections. Data from phase IIIa studies confirm the reduction of postprandial glucose excursions that can be achieved with faster aspart.

Authors+Show Affiliations

AUF DER BULT, Diabetes Center for Children and Adolescents, Janusz-Korczak-Allee 12, 30173, Hannover, Germany. biester@hka.de.AUF DER BULT, Diabetes Center for Children and Adolescents, Janusz-Korczak-Allee 12, 30173, Hannover, Germany.AUF DER BULT, Diabetes Center for Children and Adolescents, Janusz-Korczak-Allee 12, 30173, Hannover, Germany.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28940145

Citation

Biester, Torben, et al. "Pharmacological Properties of Faster-Acting Insulin Aspart." Current Diabetes Reports, vol. 17, no. 11, 2017, p. 101.
Biester T, Kordonouri O, Danne T. Pharmacological Properties of Faster-Acting Insulin Aspart. Curr Diab Rep. 2017;17(11):101.
Biester, T., Kordonouri, O., & Danne, T. (2017). Pharmacological Properties of Faster-Acting Insulin Aspart. Current Diabetes Reports, 17(11), p. 101. doi:10.1007/s11892-017-0931-y.
Biester T, Kordonouri O, Danne T. Pharmacological Properties of Faster-Acting Insulin Aspart. Curr Diab Rep. 2017 Sep 23;17(11):101. PubMed PMID: 28940145.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacological Properties of Faster-Acting Insulin Aspart. AU - Biester,Torben, AU - Kordonouri,Olga, AU - Danne,Thomas, Y1 - 2017/09/23/ PY - 2017/9/24/entrez PY - 2017/9/25/pubmed PY - 2018/1/16/medline KW - CSII KW - Diabetes KW - Faster aspart KW - Insulin KW - Pharmacodynamics KW - Pharmacokinetic SP - 101 EP - 101 JF - Current diabetes reports JO - Curr. Diab. Rep. VL - 17 IS - 11 N2 - PURPOSE OF REVIEW: Faster aspart is a new formulation of insulin aspart (IAsp) produced by adding the excipients niacinamide and L-arginine. As this new, "ultra-rapid insulin" is available in the EU-market and Canada, the pharmacokinetic and pharmacodynamics data is summarized. RECENT FINDINGS: Faster aspart shows an earlier onset of appearance of insulin in the bloodstream after subcutaneous administration and an earlier onset of glucose-lowering action and a higher glycemic effect within the first 30 min. Faster aspart administered by pump is indeed faster than conventional aspart with a faster on (- 11 min), faster off (- 24 min), and more than 100% greater insulin action within the first 30 min. Tolerability of faster aspart is similar to that of Iasp; the same holds true for compatibility in pump use. Faster aspart shows a faster occurrence of insulin in the blood compared with IAsp in subcutaneous injection. Improvements over current analogs may be more pronounced in pumps than with injections. Data from phase IIIa studies confirm the reduction of postprandial glucose excursions that can be achieved with faster aspart. SN - 1539-0829 UR - https://www.unboundmedicine.com/medline/citation/28940145/Pharmacological_Properties_of_Faster_Acting_Insulin_Aspart_ L2 - https://dx.doi.org/10.1007/s11892-017-0931-y DB - PRIME DP - Unbound Medicine ER -